Aurinia Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a corporate overview of the company at the 14th annual BIO Investor Forum, taking place October 20th – 21st in San Francisco at the Parc 55 San Francisco Hotel. The presentation will also be available using the webcast link below.
Aurinia Presentation Details
|Date:||Wednesday, October 21st, 2015|
|Time:||11:00 a.m. Pacific Standard Time|
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
Stephen Zaruby, 250-708-4293
President & Chief Executive Officer
Investor & Media:
Michael R. Martin, 250-708-4272
Chief Operating Officer
Source: Aurinia Pharmaceuticals Inc.
Released October 19, 2015